QIAGEN powered by

Clinical Oncology Summit

Part 2: May 16, 2023 (Europe) | May 18, 2023 (North America)

A two-part virtual event to help clinical diagnostic labs learn how to improve your existing pipelines for somatic NGS analysis, interpretation and reporting

Scale and optimize your current pipeline

Join thought leaders, NGS experts, lab directors, variant scientists, clinicians, and oncologists under one virtual roof at the 2023 Clinical Oncology Summit hosted by QIAGEN Digital Insights. Designed to help clinical diagnostic labs understand how they can optimize their current pipelines for somatic NGS analysis, interpretation and reporting, the Clinical Oncology Summit is a must-attend event for labs who need to reduce turnaround time, improve operational costs, and scale for higher throughput.
Learn how to scale variant interpretation and reporting for QIAGEN QIAseq, PGDx, and llumina® TruSight Oncology 500 panels.
FEATURE

SUMMIT AGENDA

Part 2: Expert Panel Discussions

Tuesday, May 16, 2023 (Europe) and Thursday, May 18, 2023 (North America)

Join us for an expert panel of key opinion leaders, lab directors and molecular pathologists that will discuss the future of comprehensive genomic profiling. Two sessions are offered for Europe and North America attendees.

Europe Session | May 16, 2023
10:00 AM (CEST)

Speakers:

Laura Lahtinen, PhD

Molecular Biologist, Hospital Nova of Central Finland

Christoph Schmitt

Biologist, GenoPath Diagnostics

Miguel Angel Molina, PhD

Laboratory Scientific Director, PanOncology

Elif Dagdan, PhD

Ruhr University Bochum, RUB Department of General Internal Medicine

North America Session | May 18, 2023
1:00 PM (EDT)

Speakers:

Elizabeth Forrester, PhD, MB (ASCP)

Founder and Technical Director at Athena Esoterix

Sarah Murray, PhD, FACMG

Director, Medical Genetics and Genomics, UCSD Center for Advanced Laboratory Medicine

Kristen Champion, PhD, FACMG

Scientific Director, Molecular Oncology at Quest Diagnostics

Martina Lefterova, MD, PhD

Vice President and Clinical Laboratory Director at Guardant

Part 1: Educational Sessions (previously aired)

Now available on-demand

Part 1 of the 2023 Clinical Oncology Summit took place on April 27th. The first installment was an educational series providing information on the latest databases, software and services for clinical somatic NGS testing from QIAGEN Digital Insights. Two sessions were offered for Europe and North America attendees. Agenda information is below.

Europe Session

Learn about QIAGEN’s solution for cloud-based NGS secondary analysis and how to get started quickly with configurable pre-made workflows.

Speaker: Leif Schauser, PhDDirector, Global Product Management, QIAGEN Digital Insights

Learn how QIAGEN’s high-quality, deeply curated knowledge can help support and scale your variant interpretation. In addition, this talk will discuss the effects of co-occurring variants on prognosis and diagnosis and how to dentify evidence-based therapy options for cancer patients for whom there is no on-label therapy.

Speaker: Kathryn Bungartz, PhD, Professional Clinical Solutions Manager, QIAGEN Digital Insights​

Learn how to use the Human Somatic Mutation Database (HSMD) as a clinical validation tool for clinical variant interpretation. In addition, this talk will show you how HSMD helps you gain genetic insights into specific cancer types and stay up-to-date with the latest treatment and clinical trial options.

Speaker: Iman Bhattacharya, Senior Global Product Marketing Manager, QIAGEN Digital Insights​

North America Session

Learn about QIAGEN’s solution for cloud-based NGS secondary analysis and how to get started quickly with configurable pre-made workflows.

Speaker: Neha Jalan, PhD, Professional Services Solution Manager, QIAGEN Digital Insights

Learn how QIAGEN’s high-quality, deeply curated knowledge can help support and scale your variant interpretation. In addition, this talk will discuss the effects of co-occurring variants on prognosis and diagnosis and how to dentify evidence-based therapy options for cancer patients for whom there is no on-label therapy.

Speaker: Sheryl Elkin, PhD, Chief Scientific Officer, QIAGEN Digital Insights

Learn how to use the Human Somatic Mutation Database (HSMD) as a clinical validation tool for clinical variant interpretation. In addition, this talk will show you how HSMD helps you gain genetic insights into specific cancer types and stay up-to-date with the latest treatment and clinical trial options.

Speaker: Uma Thirumurthi, PhD, Associate Director of Global Product Management, QIAGEN Digital Insights

Claim your free database trials and software demos

All attendees of the 2023 Clinical Oncology Summit are eligible to request free trials and demos of the featured solutions.

QIAGEN CLC Genomics Workbench

QCI Secondary Analysis

Cloud-based service for NGS secondary analysis (FASTQ to VCF)

QCI Interpret for Oncology

QCI Interpret for Oncology

Clinical decision support for variant interpretation and reporting (VCF to report)

HSMD is a somatic database with expert-curated content for oncology applications

Human Somatic Mutation Database

Somatic database to better understand precise variant function and actionability